494 related articles for article (PubMed ID: 26184689)
1. Sugar-decorated mesoporous silica nanoparticles as delivery vehicles for the poorly soluble drug celastrol enables targeted induction of apoptosis in cancer cells.
Niemelä E; Desai D; Nkizinkiko Y; Eriksson JE; Rosenholm JM
Eur J Pharm Biopharm; 2015 Oct; 96():11-21. PubMed ID: 26184689
[TBL] [Abstract][Full Text] [Related]
2. Successfully tailoring the pore size of mesoporous silica nanoparticles: exploitation of delivery systems for poorly water-soluble drugs.
Jia L; Shen J; Li Z; Zhang D; Zhang Q; Duan C; Liu G; Zheng D; Liu Y; Tian X
Int J Pharm; 2012 Dec; 439(1-2):81-91. PubMed ID: 23078857
[TBL] [Abstract][Full Text] [Related]
3. PEGylated polyaminoacid-capped mesoporous silica nanoparticles for mitochondria-targeted delivery of celastrol in solid tumors.
Choi JY; Gupta B; Ramasamy T; Jeong JH; Jin SG; Choi HG; Yong CS; Kim JO
Colloids Surf B Biointerfaces; 2018 May; 165():56-66. PubMed ID: 29453086
[TBL] [Abstract][Full Text] [Related]
4. Cancer-targeted and intracellular delivery of Bcl-2-converting peptide with functional macroporous silica nanoparticles for biosafe treatment.
Wu Y; Ge P; Xu W; Li M; Kang Q; Zhang X; Xie J
Mater Sci Eng C Mater Biol Appl; 2020 Mar; 108():110386. PubMed ID: 31923940
[TBL] [Abstract][Full Text] [Related]
5. Multifunctional mesoporous silica nanoparticles modified with tumor-shedable hyaluronic acid as carriers for doxorubicin.
Zhang J; Sun Y; Tian B; Li K; Wang L; Liang Y; Han J
Colloids Surf B Biointerfaces; 2016 Aug; 144():293-302. PubMed ID: 27107383
[TBL] [Abstract][Full Text] [Related]
6. Sterically Stabilised Polymeric Mesoporous Silica Nanoparticles Improve Doxorubicin Efficiency: Tailored Cancer Therapy.
Moodley T; Singh M
Molecules; 2020 Feb; 25(3):. PubMed ID: 32046364
[TBL] [Abstract][Full Text] [Related]
7. Intracellular degradation of multilabeled poly(ethylene imine)-mesoporous silica-silica nanoparticles: implications for drug release.
Bergman L; Kankaanpää P; Tiitta S; Duchanoy A; Li L; Heino J; Lindén M
Mol Pharm; 2013 May; 10(5):1795-803. PubMed ID: 23510188
[TBL] [Abstract][Full Text] [Related]
8. TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance.
Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Cao X; Zhang H
Mater Sci Eng C Mater Biol Appl; 2018 Mar; 84():108-117. PubMed ID: 29519418
[TBL] [Abstract][Full Text] [Related]
9. Poly(amino acid)/ZnO/mesoporous silica nanoparticle based complex drug delivery system with a charge-reversal property for cancer therapy.
Kuang Y; Chen H; Chen Z; Wan L; Liu J; Xu Z; Chen X; Jiang B; Li C
Colloids Surf B Biointerfaces; 2019 Sep; 181():461-469. PubMed ID: 31176118
[TBL] [Abstract][Full Text] [Related]
10. Controlled release of silyl ether camptothecin from thiol-ene click chemistry-functionalized mesoporous silica nanoparticles.
Yan Y; Fu J; Wang T; Lu X
Acta Biomater; 2017 Mar; 51():471-478. PubMed ID: 28131940
[TBL] [Abstract][Full Text] [Related]
11. Macroporous silica nanoparticles for delivering Bcl2-function converting peptide to treat multidrug resistant-cancer cells.
Xu W; Ge P; Niu B; Zhang X; Liu J; Xie J
J Colloid Interface Sci; 2018 Oct; 527():141-150. PubMed ID: 29787950
[TBL] [Abstract][Full Text] [Related]
12. PEG-templated mesoporous silica nanoparticles exclusively target cancer cells.
Morelli C; Maris P; Sisci D; Perrotta E; Brunelli E; Perrotta I; Panno ML; Tagarelli A; Versace C; Casula MF; Testa F; Andò S; Nagy JB; Pasqua L
Nanoscale; 2011 Aug; 3(8):3198-207. PubMed ID: 21725561
[TBL] [Abstract][Full Text] [Related]
13. A comparison of mesoporous silica nanoparticles and mesoporous organosilica nanoparticles as drug vehicles for cancer therapy.
Yue J; Luo SZ; Lu MM; Shao D; Wang Z; Dong WF
Chem Biol Drug Des; 2018 Aug; 92(2):1435-1444. PubMed ID: 29671941
[TBL] [Abstract][Full Text] [Related]
14. Targeted anticancer prodrug with mesoporous silica nanoparticles as vehicles.
Fan J; Fang G; Wang X; Zeng F; Xiang Y; Wu S
Nanotechnology; 2011 Nov; 22(45):455102. PubMed ID: 22019849
[TBL] [Abstract][Full Text] [Related]
15. PEGylated lipid bilayer-supported mesoporous silica nanoparticle composite for synergistic co-delivery of axitinib and celastrol in multi-targeted cancer therapy.
Choi JY; Ramasamy T; Kim SY; Kim J; Ku SK; Youn YS; Kim JR; Jeong JH; Choi HG; Yong CS; Kim JO
Acta Biomater; 2016 Jul; 39():94-105. PubMed ID: 27163403
[TBL] [Abstract][Full Text] [Related]
16. Hybrid mesoporous silica nanospheres modified by poly (NIPAM-co-AA) for drug delivery.
Zhang K; Zhou D; Wang Z; Zhang Y; He P
Nanotechnology; 2019 Aug; 30(35):355604. PubMed ID: 31071691
[TBL] [Abstract][Full Text] [Related]
17. Novel scheme for rapid synthesis of hollow mesoporous silica nanoparticles (HMSNs) and their application as an efficient delivery carrier for oral bioavailability improvement of poorly water-soluble BCS type II drugs.
Li T; Geng T; Md A; Banerjee P; Wang B
Colloids Surf B Biointerfaces; 2019 Apr; 176():185-193. PubMed ID: 30616109
[TBL] [Abstract][Full Text] [Related]
18. A surface-grafted ligand functionalization strategy for coordinate binding of doxorubicin at surface of PEGylated mesoporous silica nanoparticles: Toward pH-responsive drug delivery.
Zhang Q; Zhao H; Li D; Liu L; Du S
Colloids Surf B Biointerfaces; 2017 Jan; 149():138-145. PubMed ID: 27750088
[TBL] [Abstract][Full Text] [Related]
19. EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery.
Xie X; Li F; Zhang H; Lu Y; Lian S; Lin H; Gao Y; Jia L
Eur J Pharm Sci; 2016 Feb; 83():28-35. PubMed ID: 26690044
[TBL] [Abstract][Full Text] [Related]
20. Folic acid-hydrophilic polymer coated mesoporous silica nanoparticles target doxorubicin delivery.
Al-Nadaf AH; Dahabiyeh LA; Jawarneh S; Bardaweel S; Mahmoud NN
Pharm Dev Technol; 2021 Jun; 26(5):582-591. PubMed ID: 33729906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
